Bisacodyl

The brand's new Itch Relief Cooling Spray helps tackle "itchsanity" one irritation at a time. MORRISTOWN, N.J., June 16, 2025 /PRNewswire/ -- Whether it's a weekend hike, a summer camping trip, or just time spent in the backyard, skin irritations can take the fun out of outdoor activities. That's why Cortizone-10®, the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, is teaming up with the National Park Foundation and outdoor advocate Dylan Efron this summer to help more people enjoy nature—without the itch. Continue Reading Dylan Efron with Cortizone-10® Itch Relief Cooling Spray | Photo Credits: brennensmedia Cortizone-10® Itchy Bear Season To enjoy nature without the not-so-great itches, we need to make sure there are outdoor spaces worth enjoying–so Cortizone-10® is partnering with the National Park Foundation, providing $475K as part of a broader brand initiative, to help protect wildlife, preserve habitats, and support conservation efforts across some of the country's most iconic and ecologically rich landscapes. To help amplify the campaign, Dylan Efron—actor, producer, and lifelong outdoor enthusiast—is partnering with Cortizone-10®, an Opella brand, to share his favorite summer adventures and how he doesn't let itches get in the way. "Ever since I was a little kid, I've always loved being outside—all day, every day," said Dylan Efron. "That's why I am so excited to partner with Cortizone-10®. I can't even count how many times I've used this stuff in a year—let alone over my lifetime. Bug bites, poison ivy, poison oak...been there, scratched that. But no itch has ever kept me from enjoying everything the outdoors has to offer." The partnership celebrates the launch of Cortizone-10® 's new Itch Relief Cooling Spray, designed to provide fast, cooling itch relief of common skin irritations that may arise from eczema and psoriasis to bug bites and poison ivy. "We're thrilled to be teaming up with Dylan Efron and the National Park Foundation for a campaign that celebrates adventuring itch-free," said Nimit Bansal, Cortizone-10® Marketing Lead. "Cortizone-10® has always been trusted itch relief for bug bites, eczema, poison ivy, and more—and now, we're making it easier than ever for people to enjoy the outdoors without the itch getting in the way." As part of its broader "Itchsanity" campaign, Cortizone-10® is launching Itchy Bear Season, a social-first series that spotlights different "itchy bear" types one might run into in the great outdoors and shares practical tips on how to stay itch-free outside. A playful nod to natural behaviors seen in the wild, the campaign reminds us that everyone itches—but with Cortizone-10®, you don't have to suffer through it. Visit @cortizone10 on Instagram to cast your vote for itchiest bear in the brand's first-ever Big Bear Itch Off competition and follow along to learn more. The new Cortizone-10® Itch Relief Cooling Spray is available now at drugstores and major retailers nationwide. Learn more at Cortizone10.com. *2024 IQVIA Study About Cortizone-10® Cortizone-10® is the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, trusted for fast, effective relief from itch and irritation. Featuring the maximum strength of hydrocortisone available without a prescription, Cortizone-10® products are specially formulated to calm and soothe a wide range of itchy skin discomforts—including bug bites, poison ivy, eczema, psoriasis, and rashes caused by soaps, detergents, and cosmetics. With a variety of formats like creams, ointments, and sprays, Cortizone-10® delivers targeted, long-lasting relief to help people get back to feeling comfortable—so they can stay focused on what matters most. About Opella Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to put health in people's hands by making self-care as simple as it should be for over half a billion consumers worldwide. At the core of this mission is our 100 brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and four specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of North America's most loved brands, including Allegra®, Dulcolax®, Icy Hot®, Xyzal®, Unisom® and Cortizone-10®. B Corp certified in multiple markets, we are active players in the journey towards healthier people and planet. Find out more about our mission at . SOURCE Cortizone-10® WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

With Sanofi's sale of consumer health unit Opella for 10 billion euros ($11.4 billion), expect Sanofi to step up its pursuit of "bolt-on" deals, chief financial officer Francois Roger said. Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to sell a 50% controlling stake of its consumer health business Opella for 10 billion euros ($11.4 billion), the French biopharma powerhouse said on Wednesday.As for Sanofi’s next move with its fresh injection of funds, don’t expect a mega-merger any time soon.In its quarterly earnings presentation last week, in addressing the company’s plan after the sale of Opella, Sanofi Chief Financial Officer Francois Roger said that it will “explore external growth opportunities for bolt-on acquisitions.”With that, Roger cited the company’s deal last month for Dren Bio’s clinical-stage bispecific antibody, DR-0201. Sanofi paid $600 million upfront for the asset and pledged another $1.3 billion attached to launch and development milestones.“We have always been very active in the M&A space,” Roger said during the company’s quarterly call in January. “We may be a bit more in the near future due to the fact that we have a strong balance sheet.”Roger said last week that Sanofi’s “primary focus” with the added funding is to drive organic growth through R&D and other internal investments. Roger said it will bolster its “dividend policy” and enhance its share repurchase program.With the Opella deal, Sanofi will retain a 48.2% stake in the consumer healthcare outfit. Public sector investor bank Bpifrance will own a 1.8% stake in Opella and gain a seat on the board. CD&R gains a company that employs more than 11,000 people in 100 countries and operates 13 manufacturing sites and four innovation development centers. Opella is the third-largest over-the-counter business in the world, selling products such as Allegra, Doliprane and Dulcolax.With the move, Sanofi becomes a “pure-play biopharma,” it said, joining other companies in its sphere that have divested to focus on developing and marketing prescription drugs.Other drugmakers have made similar moves over the last several years, including Novartis, GSK, Johnson & Johnson and Pfizer. Sanofi’s largest acquisitions over the last few decades were a 2011 purchase of rare disease specialist Genzyme for $20.1 billion and an $11.6 billion buyout of Biogen spinout Bioverativ in 2018, which bolstered the company’s presence in hemophilia.In recent years, Sanofi has settled for smaller deals such as a $3.2 billion acquisition of Translate Bio in 2021, a $2.9 billion buyout of Provention Bio in 2023 and a $1.7 billion deal for Inhibrx in January to gain a rare disease drug.